Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer is a phase 3, randomised interventional study registered as NCT06205485 by Canadian Cancer Trials Group, with a registry enrolment figure of 250 participants, started 2024-06-26 and due to reach its primary completion in 2030-01-30. Interventions recorded: Leucovorin; Oxaliplatin; Fluoruracil; Capecitabine; Radiation. Conditions listed: Rectal Cancer. Primary outcome: Clinical response rate upon re-staging; Quality of Life defined using the LARS score. Colorectal eligibility wording from the registry: "* Histologically confirmed invasive, well-moderately differentiated rectal adenocarcinoma, mismatch repair proficient". Sites: Canada, United States. No results are recorded here; the registry entry is the source.